Heart Disease News and Research

Latest Heart Disease News and Research

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

Specific inflammatory factor may be responsible for aortic stenosis development

Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.

15 Mar 2011

Innovative orthopedic operation using 'telescoping rods' performed at HSS

An innovative operation using "telescoping rods" performed at Hospital for Special Surgery in Manhattan enabled a young Long Island boy to walk for the first time, and the child and his mother are going to Washington, D.C., to tell their story.

15 Mar 2011

Cellpraxis, USF Health, UNIFESP present and evaluate ReACT results at scientific meeting

Cellpraxis, USF Health and UNIFESP presented and evaluated the clinical results of an innovative therapy for Refractory Angina patients in a scientific meeting and workshop in São Paulo, Brazil.

15 Mar 2011

Experts to discuss on Alzheimer's disease prevention and treatment at ADI conference

From drug therapies to the right type of diet, the world's leading dementia experts will focus on the most effective methods for preventing and treating Alzheimer's disease and related dementias at the 26th Annual Conference of Alzheimer's Disease International.

15 Mar 2011

New report finds nearly 15 million Alzheimer's and dementia caregivers in the U.S.

According to 2011 Alzheimer's Disease Facts and Figures, released today by the Alzheimer's Association, there are nearly 15 million Alzheimer's and dementia caregivers in the United States.

15 Mar 2011

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, today announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome.

15 Mar 2011

Challenge Problems in mathematical cardiology

Did you know that heart attacks can give you mathematics? That statement appears on the web site of James Keener, who works in the mathematics of cardiology. This area has many problems that are ripe for unified attack by mathematicians, clinicians, and biomedical engineers.

15 Mar 2011

Global chronic disease burdens are increasing rapidly: Research

Those working for healthier humans around the globe are making headway in fighting communicable diseases such as AIDS, malaria and diarrheal illness, according to research from the Frederick S. Pardee Center for International Futures in the University of Denver's Josef Korbel School of International Studies.

15 Mar 2011

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

Bariatric surgery can result in long-term weight loss and significant reductions in cardiac and other risk factors for some severely obese adults, according to a scientific statement from the American Heart Association.

15 Mar 2011

Pico-Tesla receives ISO certification for Resonator device

Pico-Tesla, The Magneceutical Company, has received the International Organization for Standardization 13485:2003 certificate for the "design, development, production, manufacture and distribution of resonator systems that generate a low-level electromagnetic field for the therapeutic treatment of disease."

15 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

14 Mar 2011

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Health Robotics today announced that it recently signed an exclusive distribution agreement for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies with Israel-based medical technology leader Gamida MedEquip Ltd.

14 Mar 2011

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.

14 Mar 2011

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Medtronic, Inc. today announced the global launch of a new tricuspid ring for the treatment of tricuspid valve disease. Called the Contour 3D™ Annuloplasty Ring, the device is designed to restore normal valve function by remodeling the natural valve's shape and size. The Contour 3D Ring is approved for use in the U.S., Europe and several other countries.

14 Mar 2011

Indium oxine in development at Positron's Crown Point facility

Positron Corporation a molecular imaging company announced today that it is developing indium oxine, a radiopharmaceutical widely used for the radiolabeling of blood elements. This project signifies Positron's entrance into direct radiopharmaceutical manufacturing and sales; indium oxine is the first new product in development at Positron's research, development and manufacturing facility in Crown Point, Indiana.

14 Mar 2011

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

14 Mar 2011

Fysicon to customize Merge solutions for BeNeLux market

Merge Healthcare Incorporated, a global corporation dedicated to health IT interoperability solutions, today announced the expansion of its existing software relationship with Fysicon, the dominant Dutch distributor of medical imaging solutions for radiology and cardiology. Fysicon will customize Merge solutions to improve its specific portfolio of image management products for the BeNeLux market

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Heart Disease News and Research

Latest Heart Disease News and Research

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Specific inflammatory factor may be responsible for aortic stenosis development

Innovative orthopedic operation using 'telescoping rods' performed at HSS

Cellpraxis, USF Health, UNIFESP present and evaluate ReACT results at scientific meeting

Experts to discuss on Alzheimer's disease prevention and treatment at ADI conference

New report finds nearly 15 million Alzheimer's and dementia caregivers in the U.S.

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Challenge Problems in mathematical cardiology

Global chronic disease burdens are increasing rapidly: Research

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

Pico-Tesla receives ISO certification for Resonator device

Bayer receives FDA approval for Gadavist Injection

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Indium oxine in development at Positron's Crown Point facility

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Fysicon to customize Merge solutions for BeNeLux market

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Heart Disease News and Research

Latest Heart Disease News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in